We're building a better ClinicalTrials.gov. Check it out and tell us what you think!
ClinicalTrials.gov Menu

Lumigan Versus Cosopt

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT00273455
Recruitment Status : Completed
First Posted : January 9, 2006
Last Update Posted : November 19, 2008
Information provided by:
Pharmaceutical Research Network

Brief Summary:
To compare the intraocular pressure effect and safety of the dorzolamide/timolol fixed combination given twice daily versus bimatoprost given once every evening in patients with open-angle glaucoma in patients insufficiently controlled on latanoprost monotherapy

Condition or disease Intervention/treatment Phase
Open-Angle Glaucoma Drug: bimatoprost 0.03% Drug: dorzolamide 2%/timolol maleate 0.5% fixed combination Drug: placebo Phase 4

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Enrollment : 34 participants
Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: Double
Primary Purpose: Treatment
Study Start Date : January 2006
Actual Study Completion Date : May 2007

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Glaucoma
Drug Information available for: Bimatoprost

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • adults with a diagnosis of bilateral open-angle glaucoma including: primary, pigment dispersion or exfoliation in both eyes
  • on no therapy the intraocular pressure should be 22-29 mm Hg inclusive at the 8:00 AM measurement
  • visual acuity should be 20/200 or better in each eye

Exclusion Criteria:

  • historical failure to respond to topical beta-blockers in a clinically meaningful manner
  • any contraindication to study medications
  • any anticipated change, or modification in the 6 weeks prior to Visit 1, in systemic hypertensive therapy during the trial

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00273455

Layout table for location information
United States, Kentucky
Taustine Eye Center
Louisville, Kentucky, United States, 40217
United States, South Carolina
Glaucoma Consultants & Center for Eye Research, PA
Mt. Pleasant, South Carolina, United States, 29464
United States, Texas
Houston Eye Associates
Houston, Texas, United States, 77025
Sponsors and Collaborators
Pharmaceutical Research Network
Layout table for investigator information
Study Director: William C. Stewart, MD Pharmaceutical Research Network, LLC
Principal Investigator: Robert D. Williams, MD Taustine Eye Center
Principal Investigator: Robert H. Stewart, MD Houston Eye Associates
Principal Investigator: Elizabeth D. Sharpe, MD Glaucoma Consultants & Center for Eye Research, PA
Layout table for additonal information
ClinicalTrials.gov Identifier: NCT00273455    
Other Study ID Numbers: PRN 05-017
First Posted: January 9, 2006    Key Record Dates
Last Update Posted: November 19, 2008
Last Verified: November 2008
Additional relevant MeSH terms:
Layout table for MeSH terms
Glaucoma, Open-Angle
Ocular Hypertension
Eye Diseases
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action
Adrenergic beta-Antagonists
Adrenergic Antagonists
Adrenergic Agents
Neurotransmitter Agents
Physiological Effects of Drugs
Anti-Arrhythmia Agents
Antihypertensive Agents
Carbonic Anhydrase Inhibitors